A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Pegargiminase (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Polaris Pharmaceuticals
  • Most Recent Events

    • 02 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 17 Nov 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
    • 17 Nov 2015 Planned End Date changed from 1 Aug 2016 to 1 May 2016, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top